Neurogene financials
$28.39−0.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $925.0K | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $925.0K | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | — | — |
| Operating income | -$36.7M | -$33.3M | -$27.5M | -$23.8M | -$26.1M | -$25.9M | -$21.5M | -$22.2M | -$20.1M | -$18.8M | -$14.7M |
| Net income | -$34.5M | -$30.9M | -$24.7M | -$21.0M | -$22.0M | -$22.6M | -$19.5M | -$20.2M | -$18.5M | -$16.9M | $2.4M |
| Net margin | — | — | — | — | — | — | — | — | −1999.1% | — | — |
| Diluted EPS | $-1.53 | $-1.39 | $-1.12 | $-0.99 | $-1.05 | $-1.08 | $-1.00 | $-1.19 | $-1.09 | $-1.00 | $1.02 |
| EBITDA | -$35.9M | -$32.5M | -$26.8M | -$23.0M | -$25.3M | -$25.2M | -$20.7M | -$21.4M | -$19.3M | -$18.0M | -$13.9M |
| Operating cash flow | -$23.8M | -$26.1M | -$17.4M | -$19.5M | -$19.5M | -$20.8M | -$17.5M | -$15.6M | -$15.9M | -$21.6M | -$17.0M |
| Free cash flow | -$24.1M | -$26.4M | -$17.6M | -$19.6M | -$19.6M | -$21.6M | -$17.6M | -$15.7M | -$16.4M | -$21.7M | -$17.1M |
| Diluted shares | 22.6M | 22.3M | 22.1M | 21.2M | 21.1M | 21.0M | 19.5M | 17.0M | 16.9M | 16.9M | 2.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $112.5M | $124.2M | $103.8M | $71.0M | $58.8M | $70.8M |
| Short-term investments | $112.9M | $119.0M | $165.2M | $194.4M | $215.7M | $221.8M |
| Total debt | $8.0K | $13.0K | $19.0K | $38.0K | $51.0K | $65.0K |
| Total assets | $244.4M | $263.1M | $288.6M | $287.8M | $297.3M | $315.3M |
| Total liabilities | $27.2M | $25.4M | $23.7M | $22.3M | $24.1M | $23.5M |
| Shareholders' equity | $217.1M | $237.8M | $264.9M | $265.5M | $273.3M | $291.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology